Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
Biomarkers have the potential to inform the drug development process for both large and small molecule drugs. Learn more about our ability to carry out a wide variety of biomarker testing for both types of drugs: https://lnkd.in/egrVJ2Y
A brand new type of cancer drug that acts as a ‘Trojan horse’ to kill tumor cells from within has shown promise in patients with six different cancer types. Read more about the Phase I/II global clinical trial results via PharmaTimes Media Ltd: https://lnkd.in/efBfMQD
If you are attending the EIP Symposium in Lisbon next week, be sure to mark these scientific sessions in your calendar which will be presented by our Global CSO and leading immunogenicity expert Arno Kromminga. See full session details here: https://lnkd.in/guvrrmg
February 13, 2019A Dose of Pharma and Biotech News: February 13, 2019
February 6, 2019BioAgilytix Team Q&A: Meet David Rusnak, Director of Laboratory Systems and Automation at BioAgilytix
February 7, 2019BioAgilytix Welcomes Lydia Michaut, Ph.D. to Team as Scientific Officer
January 1, 2019BioAgilytix Announces Several Promotions within Its Leadership Team
May 9, 2018Evaluating the Immunogenicity of Antibody–drug Conjugates
April 16, 2018Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars